{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T12:28:53Z","timestamp":1786883333044,"version":"build-2736575974"},"reference-count":152,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["SR\/PURSE\/2023\/169(G)"],"award-info":[{"award-number":["SR\/PURSE\/2023\/169(G)"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017531","name":"Gandhi Institute of Technology and Management","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017531","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008333","name":"University of Alabama at Birmingham","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008333","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the National Cancer Center"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jncc.2025.09.006","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T07:14:17Z","timestamp":1762586057000},"page":"361-378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cytoskeletal dynamics in breast cancer: mechanistic insights and therapeutic opportunities"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2448-1681","authenticated-orcid":false,"given":"RamaRao","family":"Malla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0234-791X","authenticated-orcid":false,"given":"Anshu","family":"Tumbali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7991-9893","authenticated-orcid":false,"given":"Pavani","family":"Chode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4557-7241","authenticated-orcid":false,"given":"Krithika","family":"Manda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2275-9281","authenticated-orcid":false,"given":"Anuveda Sree","family":"Samudrala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9368-3574","authenticated-orcid":false,"given":"Yerusha","family":"Nuthalapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8377-7190","authenticated-orcid":false,"given":"Charanteja","family":"Mangam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2753-0779","authenticated-orcid":false,"given":"Priyamvada","family":"Bhamidipati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5577-0879","authenticated-orcid":false,"given":"Mundla","family":"Srilatha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4989-5234","authenticated-orcid":false,"given":"Ganji Purnachandra","family":"Nagaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jncc.2025.09.006_bib0001","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast cancer: pathogenesis and treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"10.1016\/j.jncc.2025.09.006_bib0002","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.7150\/ijbs.44943","article-title":"Mechanical tumor microenvironment and transduction: cytoskeleton mediates cancer cell invasion and metastasis","volume":"16","author":"Li","year":"2020","journal-title":"Int J Biol Sci"},{"issue":"5","key":"10.1016\/j.jncc.2025.09.006_bib0003","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1007\/s11010-024-05175-x","article-title":"Mechanisms of breast cancer metastasis: the role of extracellular matrix","volume":"480","author":"Chen","year":"2025","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.jncc.2025.09.006_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2025.1538806","article-title":"Role of the cytoskeleton in cellular reprogramming: effects of biophysical and biochemical factors","volume":"12","author":"Momotyuk","year":"2025","journal-title":"Front Mol Biosci"},{"issue":"11","key":"10.1016\/j.jncc.2025.09.006_bib0005","first-page":"385","article-title":"Cytoskeletal remodeling in cancer","volume":"9","author":"Aseervatham","year":"2020","journal-title":"Biology (Basel)"},{"issue":"7","key":"10.1016\/j.jncc.2025.09.006_bib0006","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cmet.2021.05.009","article-title":"Mechano-induced cell metabolism promotes microtubule glutamylation to force metastasis","volume":"33","author":"Torrino","year":"2021","journal-title":"Cell Metab"},{"key":"10.1016\/j.jncc.2025.09.006_bib0007","article-title":"Paclitaxel resistance in breast cancer: current challenges and recent advanced therapeutic strategies","volume":"43","author":"Abouzeid","year":"2025","journal-title":"Cancer Treat Res Commun"},{"issue":"6","key":"10.1016\/j.jncc.2025.09.006_bib0008","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1021\/acsomega.4c08140","article-title":"Role of cell adhesion in cancer metastasis formation: a review","volume":"10","author":"Burcik","year":"2025","journal-title":"ACS Omega"},{"issue":"3","key":"10.1016\/j.jncc.2025.09.006_bib0009","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s11517-021-02318-w","article-title":"Altered mechanical properties of actin fibers due to breast cancer invasion: parameter identification based on micropipette aspiration and multiscale tensegrity modeling","volume":"59","author":"Tabatabaei","year":"2021","journal-title":"Med Biol Eng Comput"},{"issue":"3","key":"10.1016\/j.jncc.2025.09.006_bib0010","doi-asserted-by":"crossref","first-page":"G490","DOI":"10.1152\/ajpgi.00229.2019","article-title":"Group II p21-activated kinase, PAK4, is needed for activation of focal adhesion kinases, MAPK, GSK3, and \u03b2-catenin in rat pancreatic acinar cells","volume":"318","author":"Ramos-\u00c1lvarez","year":"2020","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"9","key":"10.1016\/j.jncc.2025.09.006_bib0011","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.3390\/ijms22094425","article-title":"Small GTPases of the Rab and Arf families: key regulators of intracellular trafficking in neurodegeneration","volume":"22","author":"Arrazola Sastre","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.jncc.2025.09.006_bib0012","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.bbamcr.2018.07.009","article-title":"Rab and Arf proteins at the crossroad between membrane transport and cytoskeleton dynamics","volume":"1865","author":"Kjos","year":"2018","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"2","key":"10.1016\/j.jncc.2025.09.006_bib0013","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s10549-019-05463-x","article-title":"Microtubule-associated tumor suppressors as prognostic biomarkers in breast cancer","volume":"179","author":"Rodrigues-Ferreira","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.jncc.2025.09.006_bib0014","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s12551-021-00811-y","article-title":"Biophysical interactions between components of the tumor microenvironment promote metastasis","volume":"13","author":"Vasilaki","year":"2021","journal-title":"Biophys Rev"},{"issue":"4","key":"10.1016\/j.jncc.2025.09.006_bib0015","first-page":"833","article-title":"Neoplastic progression of the human breast cancer cell line G3S1 is associated with elevation of cytoskeletal dynamics and upregulation of MT1-MMP","volume":"36","author":"Tolde","year":"2010","journal-title":"Int J Oncol"},{"issue":"1","key":"10.1016\/j.jncc.2025.09.006_bib0016","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1186\/s12967-025-06422-5","article-title":"Epithelial-mesenchymal transition orchestrates tumor microenvironment: current perceptions and challenges","volume":"23","author":"Xie","year":"2025","journal-title":"J Transl Med"},{"issue":"10","key":"10.1016\/j.jncc.2025.09.006_bib0017","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.3390\/cells9102167","article-title":"Rho GTPases: big players in breast cancer initiation, metastasis and therapeutic responses","volume":"9","author":"Humphries","year":"2020","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.jncc.2025.09.006_bib0018","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0092-8674(82)90400-7","article-title":"The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells","volume":"31","author":"Moll","year":"1982","journal-title":"Cell"},{"issue":"10179","key":"10.1016\/j.jncc.2025.09.006_bib0019","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/S0140-6736(18)33137-4","article-title":"Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37\u2008298 women with early breast cancer in 26 randomised trials","volume":"393","year":"2019","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.jncc.2025.09.006_bib0020","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000038508","article-title":"HER2\/PI3K\/AKT pathway in HER2-positive breast cancer: a review","volume":"103","author":"Pan","year":"2024","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.jncc.2025.09.006_bib0021","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jncc.2025.09.006_bib0022","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1186\/s13104-018-3477-4","article-title":"Cytokeratin 5\/6 and cytokeratin 8\/18 expression in triple negative breast cancers: clinicopathologic significance in South-Asian population","volume":"11","author":"Hashmi","year":"2018","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.jncc.2025.09.006_bib0023","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2147\/JEP.S512099","article-title":"Aaptamine alters vimentin expression and migration capability of triple-negative breast cancer cells","volume":"17","author":"Khairani","year":"2025","journal-title":"J Exp Pharmacol"},{"issue":"12","key":"10.1016\/j.jncc.2025.09.006_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0279746","article-title":"The role of activated androgen receptor in cofilin phospho-regulation depends on the molecular subtype of TNBC cell line and actin assembly dynamics","volume":"17","author":"Tahtamouni","year":"2022","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.jncc.2025.09.006_bib0025","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.3390\/ijms25084530","article-title":"Imbalance between actin isoforms contributes to tumour progression in taxol-resistant triple-negative breast cancer cells","volume":"25","author":"Dugina","year":"2024","journal-title":"IInt J Mol Sci"},{"issue":"12","key":"10.1016\/j.jncc.2025.09.006_bib0026","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/j.bpj.2025.04.030","article-title":"F-actin dynamics regulates collective cell migration by modulating cell shape and stress correlation","volume":"124","author":"Kong","year":"2025","journal-title":"Biophys J"},{"key":"10.1016\/j.jncc.2025.09.006_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2022.106207","article-title":"PAK-dependent regulation of actin dynamics in breast cancer cells","volume":"146","author":"Best","year":"2022","journal-title":"Int J Biochem Cell Biol"},{"issue":"8","key":"10.1016\/j.jncc.2025.09.006_bib0028","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.3390\/ijms26083885","article-title":"The role of the p21-activated kinase family in tumor immunity","volume":"26","author":"Lu","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jncc.2025.09.006_bib0029","article-title":"Cofilin: a promising protein implicated in cancer metastasis and apoptosis. Review","volume":"9","author":"Xu","year":"2021","journal-title":"Front Cell Dev Biol."},{"issue":"2","key":"10.1016\/j.jncc.2025.09.006_bib0030","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/sj.embor.7400079","article-title":"p41-Arc subunit of human Arp2\/3 complex is a p21-activated kinase-1-interacting substrate","volume":"5","author":"Vadlamudi","year":"2004","journal-title":"EMBO Rep"},{"key":"10.1016\/j.jncc.2025.09.006_bib0031","article-title":"Targeting PAK1 suppresses tumor progression by promoting mRNA decay of oncogenic factors and enhancing chemotherapeutic efficacy in colorectal cancer","author":"Pan","year":"2025","journal-title":"Genes & Dis"},{"issue":"7","key":"10.1016\/j.jncc.2025.09.006_bib0032","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.263574","article-title":"Regulation of cell migration by extracellular matrix mechanics at a glance","volume":"138","author":"Allan","year":"2025","journal-title":"J Cell Sci"},{"key":"10.1016\/j.jncc.2025.09.006_bib0033","article-title":"PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and Tamoxifen in a luminal A breast cancer model","author":"Schwarzmueller","year":"2025","journal-title":"BioRxiv. Posted"},{"key":"10.1016\/j.jncc.2025.09.006_bib0034","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74081-1","article-title":"PAK4 methylation by the methyltransferase SETD6 attenuates cell adhesion","volume":"10","author":"Vershinin","year":"2020","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.jncc.2025.09.006_bib0035","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1158\/1535-7163.MCT-24-0404","article-title":"Novel combination therapy targeting oncogenic signaling kinase P21-activated kinase 1 and chemotherapeutic drugs against triple-negative breast cancer","volume":"24","author":"Ezhil","year":"2025","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.jncc.2025.09.006_bib0036","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41419-025-07657-2","article-title":"PAK5 promotes the trastuzumab resistance by increasing HER2 nuclear accumulation in HER2-positive breast cancer","volume":"16","author":"Zhao","year":"2025","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jncc.2025.09.006_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2021.108967","article-title":"Shear stress triggered circular dorsal ruffles formation to facilitate cancer cell migration","volume":"709","author":"Qin","year":"2021","journal-title":"Arch Biochem Biophys"},{"issue":"3","key":"10.1016\/j.jncc.2025.09.006_bib0038","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/cbdd.13808","article-title":"Focal adhesion kinase-an emerging viable target in cancer and development of focal adhesion kinase inhibitors","volume":"97","author":"Chauhan","year":"2021","journal-title":"Chem Biol Drug Des"},{"issue":"1","key":"10.1016\/j.jncc.2025.09.006_bib0039","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12943-024-01944-w","article-title":"ZNF460-mediated circRPPH1 promotes TNBC progression through ITGA5-induced FAK\/PI3K\/AKT activation in a ceRNA manner","volume":"23","author":"Zhang","year":"2024","journal-title":"Mol Cancer"},{"issue":"Pt 3","key":"10.1016\/j.jncc.2025.09.006_bib0040","article-title":"Effects of pleiotrophin (PTN) on the FAK inhibitor Y15 in breast cancer cells","volume":"280","author":"Ding","year":"2024","journal-title":"Int J Biol Macromol"},{"issue":"4","key":"10.1016\/j.jncc.2025.09.006_bib0041","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3390\/cancers13040645","article-title":"Focal adhesion kinase fine tunes multifaced signals toward breast cancer progression","volume":"13","author":"Rigiracciolo","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.jncc.2025.09.006_bib0042","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40164-023-00446-7","article-title":"Focal adhesion kinase: from biological functions to therapeutic strategies","volume":"12","author":"Tan","year":"2023","journal-title":"Exp Hematol Oncol"},{"issue":"4","key":"10.1016\/j.jncc.2025.09.006_bib0043","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3390\/cancers13040645","article-title":"Focal adhesion kinase fine tunes multifaced signals toward breast cancer progression","volume":"13","author":"Rigiracciolo","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jncc.2025.09.006_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175694","article-title":"Dual roles of FAK in tumor angiogenesis: a review focused on pericyte FAK","volume":"947","author":"Zhang","year":"2023","journal-title":"Eur J Pharmacol"},{"issue":"19","key":"10.1016\/j.jncc.2025.09.006_bib0045","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910829","article-title":"ADP-ribosylation as post-translational modification of proteins: use of inhibitors in cancer control","volume":"22","author":"Poltronieri","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.jncc.2025.09.006_bib0046","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3892\/ol.2024.14413","article-title":"Association of ADP-ribosylation factor family genes with prognosis and immune infiltration of breast cancer","volume":"27","author":"Yang","year":"2024","journal-title":"Oncol Lett"},{"issue":"36","key":"10.1016\/j.jncc.2025.09.006_bib0047","doi-asserted-by":"crossref","first-page":"58111","DOI":"10.18632\/oncotarget.11185","article-title":"Suppression of breast cancer metastasis through the inactivation of ADP-ribosylation factor 1","volume":"7","author":"Xie","year":"2016","journal-title":"Oncotarget"},{"issue":"36","key":"10.1016\/j.jncc.2025.09.006_bib0048","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1038\/onc.2011.100","article-title":"ARF1 controls proliferation of breast cancer cells by regulating the retinoblastoma protein","volume":"30","author":"Boulay","year":"2011","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.jncc.2025.09.006_bib0049","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.cmet.2024.09.013","article-title":"Adipocyte-derived glutathione promotes obesity-related breast cancer by regulating the SCARB2-ARF1-mTORC1 complex","volume":"37","author":"Zhao","year":"2025","journal-title":"Cell Metab"},{"issue":"9","key":"10.1016\/j.jncc.2025.09.006_bib0050","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/j.cellsig.2013.05.011","article-title":"ARF1 controls Rac1 signaling to regulate migration of MDA-MB-231 invasive breast cancer cells","volume":"25","author":"Lewis-Saravalli","year":"2013","journal-title":"Cell Signal"},{"issue":"3","key":"10.1016\/j.jncc.2025.09.006_bib0051","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.cellsig.2014.11.032","article-title":"ARF1 regulates adhesion of MDA-MB-231 invasive breast cancer cells through formation of focal adhesions","volume":"27","author":"Schlienger","year":"2015","journal-title":"Cell Signal"},{"issue":"1","key":"10.1016\/j.jncc.2025.09.006_bib0052","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1091\/mbc.e13-06-0335","article-title":"ARF1 regulates the Rho\/MLC pathway to control EGF-dependent breast cancer cell invasion","volume":"25","author":"Schlienger","year":"2014","journal-title":"Mol Biol Cell"},{"issue":"13","key":"10.1016\/j.jncc.2025.09.006_bib0053","doi-asserted-by":"crossref","first-page":"15811","DOI":"10.18632\/oncotarget.7515","article-title":"ADP-ribosylation factor 1 expression regulates epithelial-mesenchymal transition and predicts poor clinical outcome in triple-negative breast cancer","volume":"7","author":"Schlienger","year":"2016","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.jncc.2025.09.006_bib0054","doi-asserted-by":"crossref","first-page":"5687","DOI":"10.1074\/jbc.M113.516047","article-title":"The adaptor proteins p66Shc and Grb2 regulate the activation of the GTPases ARF1 and ARF6 in invasive breast cancer cells","volume":"289","author":"Haines","year":"2014","journal-title":"J Biol Chem"},{"issue":"52","key":"10.1016\/j.jncc.2025.09.006_bib0055","doi-asserted-by":"crossref","first-page":"36425","DOI":"10.1074\/jbc.M803603200","article-title":"ADP-ribosylation factor 1 controls the activation of the phosphatidylinositol 3-kinase pathway to regulate epidermal growth factor-dependent growth and migration of breast cancer cells","volume":"283","author":"Boulay","year":"2008","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/j.jncc.2025.09.006_bib0056","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1074\/jbc.M116.770909","article-title":"A trimer consisting of the tubulin-specific chaperone D (TBCD), regulatory GTPase ARL2, and \u03b2-tubulin is required for maintaining the microtubule network","volume":"292","author":"Francis","year":"2017","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.jncc.2025.09.006_bib0057","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175164","article-title":"The abundance of the ARL2 GTPase and its GAP, ELMOD2, at mitochondria are modulated by the fusogenic activity of mitofusins and stressors","volume":"12","author":"Newman","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jncc.2025.09.006_bib0058","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.yexcr.2006.10.024","article-title":"ADP ribosylation factor like 2 (Arl2) protein influences microtubule dynamics in breast cancer cells","volume":"313","author":"Beghin","year":"2007","journal-title":"Exp Cell Res"},{"issue":"2","key":"10.1016\/j.jncc.2025.09.006_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2019.111624","article-title":"Up-regulated ADP-Ribosylation factor 3 promotes breast cancer cell proliferation through the participation of FOXO1","volume":"384","author":"Huang","year":"2019","journal-title":"Exp Cell Res"},{"issue":"2","key":"10.1016\/j.jncc.2025.09.006_bib0060","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.canlet.2011.09.028","article-title":"Regulation of ADP-ribosylation factor 4 expression by small leucine zipper protein and involvement in breast cancer cell migration","volume":"314","author":"Jang","year":"2012","journal-title":"Cancer Lett"},{"issue":"10","key":"10.1016\/j.jncc.2025.09.006_bib0061","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1016\/j.apsb.2023.06.008","article-title":"Arf6 as a therapeutic target: structure, mechanism, and inhibitors","volume":"13","author":"Sun","year":"2023","journal-title":"Acta Pharmaceutica Sinica B"},{"issue":"5","key":"10.1016\/j.jncc.2025.09.006_bib0062","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.3390\/cells10051080","article-title":"Microtubule-associated protein ATIP3, an emerging target for personalized medicine in breast cancer","volume":"10","author":"Haykal","year":"2021","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.jncc.2025.09.006_bib0063","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00018-020-03614-8","article-title":"Reciprocal regulation of Aurora kinase A and ATIP3 in the control of metaphase spindle length","volume":"78","author":"Nehlig","year":"2021","journal-title":"Cell Mol Life Sci"},{"issue":"9","key":"10.1016\/j.jncc.2025.09.006_bib0064","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1158\/0008-5472.CAN-12-3565","article-title":"ATIP3, a novel prognostic marker of breast cancer patient survival, limits cancer cell migration and slows metastatic progression by regulating microtubule dynamics","volume":"73","author":"Molina","year":"2013","journal-title":"Cancer Res"},{"issue":"41","key":"10.1016\/j.jncc.2025.09.006_bib0065","doi-asserted-by":"crossref","first-page":"43557","DOI":"10.18632\/oncotarget.6196","article-title":"Negative regulation of EB1 turnover at microtubule plus ends by interaction with microtubule-associated protein ATIP3","volume":"6","author":"Velot","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.jncc.2025.09.006_bib0066","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10549-018-5026-1","article-title":"Combinatorial expression of microtubule-associated EB1 and ATIP3 biomarkers improves breast cancer prognosis","volume":"173","author":"Rodrigues-Ferreira","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"10.1016\/j.jncc.2025.09.006_bib0067","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1038\/s41388-021-01655-2","article-title":"Tektin4 loss promotes triple-negative breast cancer metastasis through HDAC6-mediated tubulin deacetylation and increases sensitivity to HDAC6 inhibitor","volume":"40","author":"Ge","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.jncc.2025.09.006_bib0068","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1038\/ncomms4802","article-title":"Enriched variations in TEKT4 and breast cancer resistance to paclitaxel","volume":"5","author":"Jiang","year":"2014","journal-title":"Nat Commun"},{"issue":"17","key":"10.1016\/j.jncc.2025.09.006_bib0069","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.1002\/cam4.3141","article-title":"MASTL: a novel therapeutic target for cancer malignancy","volume":"9","author":"Fatima","year":"2020","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.jncc.2025.09.006_bib0070","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1186\/s12885-018-4600-6","article-title":"MASTL inhibition promotes mitotic catastrophe through PP2A activation to inhibit cancer growth and radioresistance in breast cancer cells","volume":"18","author":"Yoon","year":"2018","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.jncc.2025.09.006_bib0071","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1007\/s13277-015-3037-7","article-title":"Predictive value of microtubule-associated protein Tau in patients with recurrent and metastatic breast cancer treated with taxane-containing palliative chemotherapy","volume":"36","author":"Zhou","year":"2015","journal-title":"Tumour Biol"},{"issue":"1","key":"10.1016\/j.jncc.2025.09.006_bib0072","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12885-019-5287-z","article-title":"The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases","volume":"19","author":"Darlix","year":"2019","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.jncc.2025.09.006_bib0073","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00280-011-1696-7","article-title":"The role of Tau protein in resistance to paclitaxel","volume":"68","author":"Smoter","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1016\/j.jncc.2025.09.006_bib0074","doi-asserted-by":"crossref","first-page":"534","DOI":"10.4132\/KoreanJPathol.2013.47.6.534","article-title":"Microtubule-associated protein Tau, \u03b1-Tubulin and \u03b2III-Tubulin expression in breast cancer","volume":"47","author":"Im","year":"2013","journal-title":"Korean J Pathol"},{"issue":"1","key":"10.1016\/j.jncc.2025.09.006_bib0075","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3390\/cancers15010116","article-title":"Cancer cells upregulate Tau to gain resistance to DNA damaging agents","volume":"15","author":"Rico","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jncc.2025.09.006_bib0076","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.845259","article-title":"The combined use of Orf virus and PAK4 inhibitor exerts anti-tumor effect in breast cancer","volume":"13","author":"Deng","year":"2022","journal-title":"Front Microbiol"},{"issue":"15_suppl","key":"10.1016\/j.jncc.2025.09.006_bib0077","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.e13607","article-title":"Phase I, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of single-agent PF-03758309, an oral PAK inhibitor, in patients with advanced solid tumors","volume":"29","author":"Mileshkin","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jncc.2025.09.006_bib0078","doi-asserted-by":"crossref","first-page":"17573","DOI":"10.18632\/oncotarget.7466","article-title":"Activated-PAK4 predicts worse prognosis in breast cancer and promotes tumorigenesis through activation of PI3K\/AKT signaling","volume":"8","author":"He","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.jncc.2025.09.006_bib0079","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41523-023-00556-9","article-title":"Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4\/6 inhibitors in ER+ breast cancer","volume":"9","author":"Belli","year":"2023","journal-title":"NPJ Breast Cancer"},{"issue":"24","key":"10.1016\/j.jncc.2025.09.006_bib0080","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jncc.2025.09.006_bib0081","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.canlet.2020.08.006","article-title":"Combined LIM kinase 1 and p21-Activated kinase 4 inhibitor treatment exhibits potent preclinical antitumor efficacy in breast cancer","volume":"493","author":"Zhao","year":"2020","journal-title":"Cancer Lett"},{"issue":"6","key":"10.1016\/j.jncc.2025.09.006_bib0082","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129634","article-title":"The Cdc42 effector kinase PAK4 localizes to cell-cell junctions and contributes to establishing cell polarity","volume":"10","author":"Selamat","year":"2015","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.jncc.2025.09.006_bib0083","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1158\/0008-5472.CAN-12-4453","article-title":"Pak1 kinase links ErbB2 to \u03b2-catenin in transformation of breast epithelial cells","volume":"73","author":"Arias-Romero","year":"2013","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.jncc.2025.09.006_bib0084","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41416-023-02523-4","article-title":"PAK inhibitor FRAX486 decreases the metastatic potential of triple-negative breast cancer cells by blocking autophagy","volume":"130","author":"Lyu","year":"2024","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.jncc.2025.09.006_bib0085","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10549-019-05329-2","article-title":"Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer","volume":"177","author":"Korobeynikov","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.jncc.2025.09.006_bib0086","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13058-015-0564-5","article-title":"Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents","volume":"17","author":"Ong","year":"2015","journal-title":"Breast Cancer Res"},{"issue":"2","key":"10.1016\/j.jncc.2025.09.006_bib0087","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1200\/JCO.1996.14.2.422","article-title":"Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group","volume":"14","author":"Trudeau","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jncc.2025.09.006_bib0088","article-title":"p21-activated kinase 1 promotes breast tumorigenesis via phosphorylation and activation of the calcium\/calmodulin-dependent protein kinase II","volume":"9","author":"Saldivar-Cer\u00f3n","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"10.1016\/j.jncc.2025.09.006_bib0089","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.518","article-title":"Effect of P21-activated kinase 1 (PAK-1) inhibition on cancer cell growth, migration, and invasion","volume":"7","author":"Najahi-Missaoui","year":"2019","journal-title":"Pharmacol Res Perspect"},{"issue":"10","key":"10.1016\/j.jncc.2025.09.006_bib0090","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.3390\/cancers11101527","article-title":"The PAK1-Stat3 signaling pathway activates IL-6 gene transcription and human breast cancer stem cell formation","volume":"11","author":"Kim","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.jncc.2025.09.006_bib0091","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/jdv.18573","article-title":"Comparison of topical benzyl benzoate vs. oral ivermectin in treating scabies: a randomized study","volume":"37","author":"Meyersburg","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.jncc.2025.09.006_bib0092","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.518","article-title":"Effect of P21-activated kinase 1 (PAK-1) inhibition on cancer cell growth, migration, and invasion","volume":"7","author":"Najahi-Missaoui","year":"2019","journal-title":"Pharmacol Res Perspect"},{"issue":"3","key":"10.1016\/j.jncc.2025.09.006_bib0093","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s10637-024-01434-2","article-title":"The suppression of cell motility through the reduction of FAK activity and expression of cell adhesion proteins by hAMSCs secretome in MDA-MB-231 breast cancer cells","volume":"42","author":"Safari","year":"2024","journal-title":"Invest New Drugs"},{"issue":"3","key":"10.1016\/j.jncc.2025.09.006_bib0094","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/mc.20380","article-title":"TAE226-induced apoptosis in breast cancer cells with overexpressed Src or EGFR","volume":"47","author":"Golubovskaya","year":"2008","journal-title":"Mol Carcinog"},{"issue":"8","key":"10.1016\/j.jncc.2025.09.006_bib0095","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.yexcr.2011.02.008","article-title":"Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo","volume":"317","author":"Kurio","year":"2011","journal-title":"Exp Cell Res"},{"issue":"3","key":"10.1016\/j.jncc.2025.09.006_bib0096","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s10549-010-0857-4","article-title":"Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells","volume":"125","author":"Hiscox","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"20","key":"10.1016\/j.jncc.2025.09.006_bib0097","doi-asserted-by":"crossref","first-page":"14845","DOI":"10.1074\/jbc.M606695200","article-title":"Cellular characterization of a novel focal adhesion kinase inhibitor","volume":"282","author":"Slack-Davis","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jncc.2025.09.006_bib0098","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejmech.2012.06.035","article-title":"Discovery and characterization of novel allosteric FAK inhibitors","volume":"61","author":"Iwatani","year":"2013","journal-title":"Eur J Med Chem"},{"issue":"34","key":"10.1016\/j.jncc.2025.09.006_bib0099","doi-asserted-by":"crossref","first-page":"6977","DOI":"10.2174\/0929867328666210331143827","article-title":"Recent advances of small molecule focal adhesion kinase (FAK) inhibitors as promising anticancer therapeutics","volume":"28","author":"Lv","year":"2021","journal-title":"Curr Med Chem"},{"issue":"13","key":"10.1016\/j.jncc.2025.09.006_bib0100","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1200\/JCO.2011.38.9346","article-title":"Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors","volume":"30","author":"Infante","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jncc.2025.09.006_bib0101","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1186\/s13104-019-4389-7","article-title":"Pharmacological profiling of a dual FAK\/IGF-1R kinase inhibitor TAE226 in cellular and in vivo tumor models","volume":"12","author":"Fukami","year":"2019","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.jncc.2025.09.006_bib0102","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115192","article-title":"Design, synthesis and evaluation of nitric oxide releasing derivatives of 2,4-diaminopyrimidine as novel FAK inhibitors for intervention of metastatic triple-negative breast cancer","volume":"250","author":"Zhang","year":"2023","journal-title":"Eur J Med Chem"},{"issue":"10","key":"10.1016\/j.jncc.2025.09.006_bib0103","doi-asserted-by":"crossref","first-page":"778","DOI":"10.4161\/cbt.9.10.11433","article-title":"Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models","volume":"9","author":"Walsh","year":"2010","journal-title":"Cancer Biol Ther"},{"issue":"2","key":"10.1016\/j.jncc.2025.09.006_bib0104","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3724\/abbs.2022008","article-title":"SY-707, an ALK\/FAK\/IGF1R inhibitor, suppresses growth and metastasis of breast cancer cells","volume":"54","author":"Liu","year":"2022","journal-title":"Acta Biochim Biophys Sin"},{"issue":"4","key":"10.1016\/j.jncc.2025.09.006_bib0105","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s11427-016-0368-y","article-title":"Lycorine inhibits breast cancer growth and metastasis via inducing apoptosis and blocking Src\/FAK-involved pathway","volume":"60","author":"Ying","year":"2017","journal-title":"Sci China Life Sci"},{"key":"10.1016\/j.jncc.2025.09.006_bib0106","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116809","article-title":"Discovery of novel chloropyramine-cinnamic acid hybrids as potential FAK inhibitors for intervention of metastatic triple-negative breast cancer","volume":"66","author":"Yang","year":"2022","journal-title":"Bioorg Med Chem"},{"issue":"8_Supplement_1","key":"10.1016\/j.jncc.2025.09.006_bib0107","article-title":"APG-2449, a novel focal adhesion kinase (FAK) inhibitor, enhances the antitumor activity of chemotherapy in preclinical models of small-cell lung cancer (SCLC) with activated FAK","volume":"85","author":"Yu","year":"2025","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.jncc.2025.09.006_bib0108","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/13543776.2024.2368742","article-title":"FAK inhibitors in cancer, a patent review - an update on progress","volume":"34","author":"Ye","year":"2024","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.jncc.2025.09.006_bib0109","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114732","article-title":"Combination of FAK inhibitor and cytokine-induced killer cell therapy: an alternative therapeutic strategy for patients with triple-negative breast cancer","volume":"163","author":"Wu","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1016\/j.jncc.2025.09.006_bib0110","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40364-024-00558-0","article-title":"Simultaneous inhibition of FAK and ROS1 synergistically repressed triple-negative breast cancer by upregulating p53 signalling","volume":"12","author":"Tan","year":"2024","journal-title":"Biomark Res"},{"issue":"9","key":"10.1016\/j.jncc.2025.09.006_bib0111","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.7150\/ijbs.81918","article-title":"Synergism of FAK and ROS1 inhibitors in the treatment of CDH1-deficient cancers mediated by FAK-YAP signaling","volume":"19","author":"Gao","year":"2023","journal-title":"Int J Biol Sci"},{"issue":"19","key":"10.1016\/j.jncc.2025.09.006_bib0112","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.3390\/cells11192988","article-title":"Combination treatment of retinoic acid plus focal adhesion kinase inhibitor prevents tumor growth and breast cancer cell metastasis","volume":"11","author":"Castro-Guijarro","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jncc.2025.09.006_bib0113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mce.2016.04.021","article-title":"Retinoic acid induces nuclear FAK translocation and reduces breast cancer cell adhesion through Moesin, FAK, and Paxillin","volume":"430","author":"Sanchez","year":"2016","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.jncc.2025.09.006_bib0114","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.omto.2021.02.014","article-title":"Involvement of actin cytoskeletal modifications in the inhibition of triple-negative breast cancer growth and metastasis by nimbolide","volume":"20","author":"Arumugam","year":"2021","journal-title":"Mol Ther Oncolytics"},{"issue":"10","key":"10.1016\/j.jncc.2025.09.006_bib0115","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1080\/15384047.2015.1071737","article-title":"The small GTPase ADP-Ribosylation Factor 1 mediates the sensitivity of triple negative breast cancer cells to EGFR tyrosine kinase inhibitors","volume":"16","author":"Haines","year":"2015","journal-title":"Cancer Biol Ther"},{"issue":"18","key":"10.1016\/j.jncc.2025.09.006_bib0116","doi-asserted-by":"crossref","first-page":"9913","DOI":"10.1073\/pnas.170290597","article-title":"Binding site of brefeldin A at the interface between the small G protein ADP-ribosylation factor 1 (ARF1) and the nucleotide-exchange factor Sec7 domain","volume":"97","author":"Robineau","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.jncc.2025.09.006_bib0117","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1074\/jbc.M111.316125","article-title":"AMF-26, a novel inhibitor of the Golgi system, targeting ADP-ribosylation factor 1 (Arf1) with potential for cancer therapy","volume":"287","author":"Ohashi","year":"2012","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.jncc.2025.09.006_bib0118","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1016\/j.apsb.2022.02.011","article-title":"Discovery of ARF1-targeting inhibitor demethylzeylasteral as a potential agent against breast cancer","volume":"12","author":"Chang","year":"2022","journal-title":"Acta Pharm Sin B"},{"issue":"4","key":"10.1016\/j.jncc.2025.09.006_bib0119","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3390\/molecules26040969","article-title":"Chlortetracycline, a novel Arf inhibitor that decreases the Arf6-dependent invasive properties of breast cancer cells","volume":"26","author":"Macia","year":"2021","journal-title":"Molecules"},{"issue":"Suppl 12","key":"10.1016\/j.jncc.2025.09.006_bib0120","doi-asserted-by":"crossref","first-page":"xii15","DOI":"10.1093\/annonc\/mdm534","article-title":"Markers predicting clinical benefit in breast cancer from microtubule-targeting agents","volume":"18","author":"Pusztai","year":"2007","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.jncc.2025.09.006_bib0121","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1470-2045(23)00051-7","article-title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial","volume":"24","author":"Tolaney","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jncc.2025.09.006_bib0122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/mpo.2950090102","article-title":"Doxorubicin, vincristine, and cis-diamminedichloroplatinum (II) therapy in patients with advanced breast cancer","volume":"9","author":"Trump","year":"1981","journal-title":"Med Pediatr Oncol"},{"issue":"6","key":"10.1016\/j.jncc.2025.09.006_bib0123","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3816\/CBC.2008.n.058","article-title":"Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes","volume":"8","author":"Yardley","year":"2008","journal-title":"Clin Breast Cancer"},{"issue":"30","key":"10.1016\/j.jncc.2025.09.006_bib0124","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.2217\/fon-2017-0283","article-title":"Eribulin in advanced breast cancer: safety, efficacy and new perspectives","volume":"13","author":"Garrone","year":"2017","journal-title":"Future Oncol"},{"issue":"9769","key":"10.1016\/j.jncc.2025.09.006_bib0125","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jncc.2025.09.006_bib0126","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-70142-7","article-title":"ATIP3 deficiency facilitates intracellular accumulation of paclitaxel to reduce cancer cell migration and lymph node metastasis in breast cancer patients","volume":"10","author":"Rodrigues-Ferreira","year":"2020","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.jncc.2025.09.006_bib0127","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s00280-017-3398-2","article-title":"Regulation of paclitaxel activity by microtubule-associated proteins in cancer chemotherapy","volume":"80","author":"Shi","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jncc.2025.09.006_bib0128","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217665","article-title":"Targeting WEE1 kinase as a therapeutic strategy in ATIP3-deficient breast cancers","volume":"620","author":"Haykal","year":"2025","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jncc.2025.09.006_bib0129","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.canlet.2019.12.023","article-title":"WEE1 inhibitor, AZD1775, overcomes trastuzumab resistance by targeting cancer stem-like properties in HER2-positive breast cancer","volume":"472","author":"Sand","year":"2020","journal-title":"Cancer Lett"},{"issue":"4","key":"10.1016\/j.jncc.2025.09.006_bib0130","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1158\/1078-0432.CCR-20-3089","article-title":"Clinical efficacy and molecular response correlates of the WEE1 inhibitor adavosertib combined with cisplatin in patients with metastatic triple-negative breast cancer","volume":"27","author":"Keenan","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.jncc.2025.09.006_bib0131","doi-asserted-by":"crossref","first-page":"e7239","DOI":"10.1371\/journal.pone.0007239","article-title":"8p22 MTUS1 gene product ATIP3 is a novel anti-mitotic protein underexpressed in invasive breast carcinoma of poor prognosis","volume":"4","author":"Rodrigues-Ferreira","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.jncc.2025.09.006_bib0132","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.122250","article-title":"Targeted inhibition of MASTL kinase activity induces apoptosis in breast cancer","volume":"334","author":"Misra","year":"2023","journal-title":"Life Sci"},{"issue":"4","key":"10.1016\/j.jncc.2025.09.006_bib0133","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10637-005-4343-5","article-title":"A phase I study of flavopiridol and docetaxel","volume":"24","author":"El-Rayes","year":"2006","journal-title":"Invest New Drugs"},{"issue":"7","key":"10.1016\/j.jncc.2025.09.006_bib0134","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3390\/ph14070647","article-title":"Discovery and characterization of a novel MASTL inhibitor MKI-2 targeting MASTL-PP2A in breast cancer cells and oocytes","volume":"14","author":"Kang","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jncc.2025.09.006_bib0135","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.571601","article-title":"MKI-1, a novel small-molecule inhibitor of MASTL, exerts antitumor and radiosensitizer activities through PP2A activation in breast cancer","volume":"10","author":"Kim","year":"2020","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.jncc.2025.09.006_bib0136","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s12032-022-01701-3","article-title":"Therapeutic natural compounds Enzastaurin and Palbociclib inhibit MASTL kinase activity preventing breast cancer cell proliferation","volume":"39","author":"Polisety","year":"2022","journal-title":"Med Oncol"},{"issue":"10","key":"10.1016\/j.jncc.2025.09.006_bib0137","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1111\/j.1349-7006.2010.01677.x","article-title":"Phase I dose escalation and pharmacokinetic study of oral enzastaurin (LY317615) in advanced solid tumors","volume":"101","author":"Mukohara","year":"2010","journal-title":"Cancer Sci"},{"issue":"6","key":"10.1016\/j.jncc.2025.09.006_bib0138","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s10637-009-9220-1","article-title":"A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen","volume":"27","author":"Mina","year":"2009","journal-title":"Invest New Drugs"},{"issue":"1","key":"10.1016\/j.jncc.2025.09.006_bib0139","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10549-010-1152-0","article-title":"Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy","volume":"124","author":"Clemons","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.jncc.2025.09.006_bib0140","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.3390\/cancers12051292","article-title":"Rho GTPases in gynecologic cancers: in-depth analysis toward the paradigm change from reactive to predictive, preventive, and personalized medical approach benefiting the patient and healthcare","volume":"12","author":"Zubor","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.jncc.2025.09.006_bib0141","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.yexcr.2014.10.012","article-title":"Quantitative imaging of focal adhesion dynamics and their regulation by HGF and Rap1 signaling","volume":"330","author":"Spanjaard","year":"2015","journal-title":"Exp Cell Res"},{"issue":"6","key":"10.1016\/j.jncc.2025.09.006_bib0142","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1158\/1078-0432.CCR-12-1359","article-title":"Biomarker analysis of neoadjuvant doxorubicin\/cyclophosphamide followed by ixabepilone or Paclitaxel in early-stage breast cancer","volume":"19","author":"Horak","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jncc.2025.09.006_bib0143","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4048\/jbc.2020.23.e11","article-title":"Analysis of Tau protein expression in predicting pathological complete response to neoadjuvant chemotherapy in different molecular subtypes of breast cancer","volume":"23","author":"Lei","year":"2020","journal-title":"J Breast Cancer"},{"issue":"1","key":"10.1016\/j.jncc.2025.09.006_bib0144","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74838-8","article-title":"Identification of drivers of breast cancer invasion by secretome analysis: insight into CTGF signaling","volume":"10","author":"Hellinger","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jncc.2025.09.006_bib0145","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/978-1-0716-2887-4_21","article-title":"Live-cell labeling and artificial intelligence approaches for high-resolution XYZT imaging of cytoskeletal dynamics during collective cell migration","volume":"2608","author":"Cammeraat","year":"2023","journal-title":"Methods Mol Biol"},{"issue":"3","key":"10.1016\/j.jncc.2025.09.006_bib0146","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00709-024-02019-9","article-title":"Deep learning-based cytoskeleton segmentation for accurate high-throughput measurement of cytoskeleton density","volume":"262","author":"Horiuchi","year":"2025","journal-title":"Protoplasma"},{"issue":"8","key":"10.1016\/j.jncc.2025.09.006_bib0147","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1158\/0008-5472.CAN-03-3383","article-title":"A serial analysis of gene expression (SAGE) database analysis of chemosensitivity: comparing solid tumors with cell lines and comparing solid tumors from different tissue origins","volume":"64","author":"Stein","year":"2004","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.jncc.2025.09.006_bib0148","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1158\/1535-7163.MCT-12-0146","article-title":"Peptidomimetic Src\/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER\/PR\/HER2-negative tumor xenografts","volume":"11","author":"Anbalagan","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.jncc.2025.09.006_bib0149","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s10549-011-1875-6","article-title":"Beyond taxanes: the next generation of microtubule-targeting agents","volume":"133","author":"Cortes","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.jncc.2025.09.006_bib0150","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1242\/jcs.02760","article-title":"Cellular adaptation to mechanical stress: role of integrins, Rho, cytoskeletal tension and mechanosensitive ion channels","volume":"119","author":"Matthews","year":"2006","journal-title":"J Cell Sci"},{"issue":"6","key":"10.1016\/j.jncc.2025.09.006_bib0151","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","article-title":"Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jncc.2025.09.006_bib0152","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41568-021-00340-6","article-title":"Targeting FAK in anticancer combination therapies","volume":"21","author":"Dawson","year":"2021","journal-title":"Nat Rev Cancer"}],"container-title":["Journal of the National Cancer Center"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667005425001188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667005425001188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T11:48:03Z","timestamp":1786880883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667005425001188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":152,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2667005425001188"],"URL":"https:\/\/doi.org\/10.1016\/j.jncc.2025.09.006","relation":{},"ISSN":["2667-0054"],"issn-type":[{"value":"2667-0054","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytoskeletal dynamics in breast cancer: mechanistic insights and therapeutic opportunities","name":"articletitle","label":"Article Title"},{"value":"Journal of the National Cancer Center","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jncc.2025.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Chinese National Cancer Center. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}